Advertisement

Topics

Galt Company Profile

23:19 EST 10th December 2018 | BioPortfolio

Every situation—whether you are responding to a regulatory requirement, addressing a competitor challenge, or augmenting your surveillance and signaling resources—calls for a distinct approach. Galt’s team of medical, scientific and technical experts will work with you to design an efficient solution that best meets your unique needs. Galt’s expertise covers the full benefit/risk spectrum, including:
Adverse event coding and electronic submission
Risk management and safety data analysis
Competitive intelligence, safety surveillance and monitoring
Pharmacoepidemiology and innovative communication solutions
At Galt, our solutions allow us to deliver results quickly, while our industry expertise ensures those results are useful

Location

46040 Center Oak Plaza, Suite 100
Sterling
Virginia
20166
United States of America

Contact

Phone: 703-421-6720
Fax: 703-421-6708
Email: info@drugsafety.com


News Articles [12 Associated News Articles listed on BioPortfolio]

Diet induced changes in the microbiota and cell composition of rabbit gut associated lymphoid tissue (GALT)

TLRY On A High, GALT Gallops, MLNT On Watch, ALRN To Report Phase II Data In Q4

The following are some of today's top gainers in the pharma/biotech sector.

$GALT filing 424B3 6,945,836 Shares of Common Stock Issuable Upon Exercise of Warrants and Conversion of Series B-3 Preferred Stock

$GALT filing 424B3 6,945,836 Shares of Common Stock Issuable Upon Exercise of Warrants and Conversion of Series B-3 Preferred Stock

GALT Vaults As NASH Research Sparks Interest, MDGL Abuzz, MACK Awaits Data

The following are some of today's top gainers in the pharma/biotech sector.

$GALT Preliminary Results from Phase 1b Clinical Trial of GR-MD-02 and KEYTRUDA® in Advanced Melanoma and Expansion of the Trial https://finance.yahoo.com/news/galectin-therapeutics-inc-announces-positive-120000449.html …

$GALT Preliminary Results from Phase 1b Clinical Trial of GR-MD-02 and KEYTRUDA® in Advanced Melanoma and Expansion of the Trial https://finance.yahoo.com/news/galectin-therapeutics-inc-announce...

CytoTools: Ein neuer Anlauf

Vor einigen Jahren galt CytoTools als aussichtsreicher Tipp im deutschen Biotechnologie-Segment, da das Unternehmen ein innovatives Produkt für einen großen Markt in der Pipeline hatte. Eine in Eur....

Biofrontera Aktie: Ein klares Kaufsignal!

Fast die gesamte letzte Woche über schauten Anleger gebannt auf die Marke von 6,10 Euro bei Biofrontera. Jene galt in der Charttechnik lange Zeit als wichtigster Widerstand und zählt mittlerweile a....

IBM - jahrelanger Konzernumbau macht sich langsam bezahlt

Künstliche Intelligenz, Datenanalyse und Cloud-Computing - das sind die treibenden Faktoren. Hat IBM das Geschäft mit der Zukunft jetzt verstanden? Lange galt IBM als abgeschrieben. Doch so langsam....

Drugs and Medications [0 Results]

None

PubMed Articles [4 Associated PubMed Articles listed on BioPortfolio]

Galactose-1-phosphate uridyltransferase (GalT), an in vivo-induced antigen of Actinobacillus pleuropneumoniae serovar 5b strain L20, provided immunoprotection against serovar 1 strain MS71.

GALT is an important antigen of Actinobacillus pleuropneumoniae (APP), which was shown to provide partial protection against APP infection in a previous study in our lab. The main purpose of the prese...

Synthesis of novel triazole-derived glycopeptides as analogs of α-dystroglycan mucins.

α-Dystroglycan (α-DG) mucins are essential for maintenance of the structural and functional stability of the muscle fiber and, when hypoglycosylated, they are directly involved in pathological proce...

Gene expression analysis of isolated salmonid GALT leucocytes in response to PAMPs and recombinant cytokines.

Increased knowledge of the immune response of the intestine, a physiologically critical organ involved in absorption, secretion and homeostasis in a non-sterile environment, is needed to better unders...

Modulation of the microbiota by oral antibiotics treats immunoglobulin A nephropathy in humanized mice.

Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. IgA is mainly produced by the gut-associated lymphoid tissue (GALT). Both experimental and clinical data su...

Clinical Trials [5 Associated Clinical Trials listed on BioPortfolio]

Residual Replication of HIV-1 in the Gut Associated Lymphoid Tissue (GALT) of Patients on Highly Active Antiretroviral Therapy (HAART): the ANRS EP 44 Study

HIV-1 cannot be eradicated from infected individuals by current antiretroviral regimens. Cellular reservoirs and tissue sanctuary sites allow latent HIV-1 persistence and ongoing low-level...

The Lymphoid Tissue Pharmacology of Antiretroviral Drugs

Hypothesis: Antiretroviral drugs (ARVs) with enhanced LT penetration characteristics in vitro and in macaques will translate into an ARV regimen with increased LN and GALT concentrations ...

Predictors of Time to Viremia With an Analytic Treatment Interruption

This is a two-center study of 30 HIV-infected participants who have been on antiretroviral therapy (ART) for at least two years. Participants will be asked to undergo LN and GALT biopsies...

HIV Persistence and Viral Reservoirs

Although highly active antiretroviral therapy (HAART) decreases HIV-associated mortality, it does not to completely restore health. Patients doing well on otherwise effective HAART remain...

Impact of Pre-ART Blood CD4+ T Cell Level on the Rectal Reservoir in Long-term HIV-1 Treated Men

Although combined antiretroviral therapy (cART) has dramatically improved quality of life and lifespan of HIV infected individuals, it still fails to eliminate viral reservoirs. The Gut As...

Companies [6 Associated Companies listed on BioPortfolio]

Galt Associates, Inc

Every situation—whether you are responding to a regulatory requirement, addressing a competitor challenge, or augmenting your surveillance and signaling resources—calls for a distinct approach. Ga...

Galt

Every situation—whether you are responding to a regulatory requirement, addressing a competitor challenge, or augmenting your surveillance and signaling resources—calls for a distinct approach. Ga...

Galt Medical

Galt Medical (www.galtmedical.com), a wholly-owned subsidiary of Theragenics Corporation® (www.theragenics.com), manufactures and distributes vascular access products used in ...

Galectin Therapeutics Inc.

Galectin Therapeutics is focusing its galectin inhibitor development efforts in two key disease areas: fibrosis and cancer.

Galectin Therapeutics, Inc.

Galectin Therapeutics (OTC: GALT) is developing promising carbohydrate-based therapies for fibrotic liver disease and cancer based on the Company’s unique understanding of ga...

More Information about "Galt" on BioPortfolio

We have published hundreds of Galt news stories on BioPortfolio along with dozens of Galt Clinical Trials and PubMed Articles about Galt for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Galt Companies in our database. You can also find out about relevant Galt Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record